FAAH selectively influences placebo effects
Open Access
- 17 September 2013
- journal article
- research article
- Published by Springer Nature in Molecular Psychiatry
- Vol. 19 (3) , 385-391
Abstract
Endogenous opioid and cannabinoid systems are thought to act synergistically regulating antinociceptive and reward mechanisms. To further understand the human implications of the interaction between these two systems, we investigated the role of the common, functional missense variant Pro129Thr of the gene coding fatty acid amide hydrolase (FAAH), the major degrading enzyme of endocannabinoids, on psychophysical and neurotransmitter (dopaminergic, opioid) responses to pain and placebo-induced analgesia in humans. FAAH Pro129/Pro129 homozygotes, who constitute nearly half of the population, reported higher placebo analgesia and more positive affective states immediately and 24 h after placebo administration; no effects on pain report in the absence of placebo were observed. Pro129/Pro129 homozygotes also showed greater placebo-induced μ-opioid, but not D2/3 dopaminergic, enhancements in neurotransmission in regions known involved in placebo effects. These results show that a common genetic variation affecting the function of the cannabinoid system is serving as a probe to demonstrate the involvement of cannabinoid and opioid transmitters on the formation of placebo effects.Keywords
This publication has 39 references indexed in Scilit:
- Role of μ-opioid system in the formation of memory of placebo responsesMolecular Psychiatry, 2012
- Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide HydrolaseThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Cocaine abuse and sensitization of striatal dopamine transmission: A critical review of the preclinical and clinical imaging literatureSynapse, 2008
- Addictions Biology: Haplotype-Based Analysis for 130 Candidate Genes on a Single ArrayAlcohol and Alcoholism, 2008
- The role of learning in nocebo and placebo effectsPain, 2008
- Bidirectional regulation of mu‐opioid and CB1‐cannabinoid receptor in rats self‐administering heroin or WIN 55,212‐2European Journal of Neuroscience, 2007
- Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid ReceptorsThe Journal of Neuroscience, 2005
- Effect of Chronic Administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Δ9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Spatial and temporal summation of sensory and affective dimensions of deep somatic painPain, 1999
- Development and validation of brief measures of positive and negative affect: The PANAS scales.Journal of Personality and Social Psychology, 1988